Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway
Apatinib potentially hindered the progression of sorafenib-resistant HCC by suppressing both EMT and the EGFR/JNK/ERK pathway.
Authors
- Zhenqiang Bi (ORCID: https://orcid.org/0000-0002-3368-6139)
- Junlin Gao
- Dejun Fan (ORCID: https://orcid.org/0000-0003-3041-0572)
- Lichao Zhu (ORCID: https://orcid.org/0000-0002-4692-0692)
- Xinxing Wang
- XIANWEN XU
- Mingze Ma (ORCID: https://orcid.org/0000-0002-0375-6597)
- Zhenhai Zhang (ORCID: https://orcid.org/0000-0002-4479-7205)
- Wei Su (ORCID: https://orcid.org/0000-0001-9634-9474)
Institutions
- Shandong University (CN)
- Qinghai Red Cross Hospital (CN)
- Shandong Provincial Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.060407
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00